Igor Stagljar is a Professor of Biochemistry and Molecular Genetics, ranked #1 in Science & Academia (Genomics & Genetics) (Top 33%).
Last updated
Igor Stagljar is a Professor at the Temerty Faculty of Medicine, University of Toronto, specializing in biochemistry, molecular genetics, and cancer research. With over two decades of experience, he focuses on proteomics, protein-protein interactions, and drug discovery, particularly in cancer signaling and membrane transport. Stagljar has published over 140 papers, secured 8 patents, and developed innovative platforms like MYTH, MaMTH, and SIMPL. He co-founded biotech companies Dualsystems Biotech and Perturba Therapeutics, translating scientific discoveries into therapies. Recognized globally, he is a member of the Royal Society of Canada, EMBO, and the Croatian Academy of Arts and Sciences. His work includes developing serological tests for SARS-CoV-2 and advancing AI-driven drug discovery.
The future of medicine is where biology meets chemistry, physics, and AI.
Favikon helps you find the right creators, analyze them in depth, reach out at scale, and track what works.